8-K: Sanuwave Health Secures $4.6 Million in Convertible Notes and Warrants Amidst Planned Merger

Sanuwave Health, Inc. has entered into a securities purchase agreement for $4.6 million in convertible notes and warrants, coinciding with a planned business combination with SEP Acquisition Corp.

Summary

• Sanuwave Health, Inc. issued approximately $4.6 million in Future Advance Convertible Promissory Notes to accredited investors on January 21, 2024.
• The notes bear a 15% annual interest rate and are convertible into common stock at $0.04 per share, subject to adjustments.
• The company also issued warrants to purchase 113.9 million shares at $0.04 per share and another 113.9 million shares at $0.067 per share, both with a five-year term.
• No cash proceeds were received by Sanuwave in this private placement, as the notes and warrants were issued in exchange for previous obligations.
• The rights of the note purchasers are subordinate to those of NH Expansion Credit Fund Holdings LP.
• Sanuwave is obligated to file a registration statement with the SEC within 60 days to register the resale of shares issuable upon conversion of the notes and exercise of the warrants, and to have it declared effective within 180 days.
• Purchasers waived the company's obligation to effect a reverse stock split by December 31, 2023, through December 31, 2024.
• In October 2023, purchasers agreed to exchange notes and warrants for common stock immediately prior to the closing of the planned business combination with SEP Acquisition Corp.
• The exchange ratio is $0.04 per share for the notes, 0.9 shares per warrant at $0.04 exercise price, and 0.85 shares per warrant at $0.067 exercise price.

Sentiment

Score: 4

Explanation: The document outlines a complex financial transaction with both positive and negative aspects. While the company secures funding and moves towards a merger, the lack of cash proceeds, high interest rate, and potential for dilution temper the overall sentiment.

Positives

• The agreement provides Sanuwave with a mechanism to convert existing debt into equity.
• The waiver of the reverse stock split obligation provides the company with more flexibility.
• The planned business combination with SEP Acquisition Corp. could provide access to public markets.

Negatives

• The company received no cash proceeds from this private placement.
• The conversion price of the notes and exercise price of the warrants are subject to adjustment, which could lead to further dilution.
• The rights of the note purchasers are subordinate to those of NH Expansion Credit Fund Holdings LP.

Risks

• The company's ability to complete the merger with SEP Acquisition Corp. is subject to various conditions, including obtaining stockholder approval and having at least $12 million at closing.
• Delays in obtaining regulatory approvals could impact the timing of the merger.
• The company may not be able to maintain the listing of its securities on Nasdaq following the merger.
• The company's actual results may differ from expectations due to economic, business, and competitive factors.
• The conversion price of the notes and exercise price of the warrants are subject to adjustment, which could lead to further dilution.

Future Outlook

The document includes forward-looking statements regarding the proposed merger with SEP Acquisition Corp. and the expected results for the combined company, but cautions that actual results may differ materially due to various risks and uncertainties.

Management Comments

• The document does not contain direct quotes from management, but it does outline the terms of the agreements and the company's obligations.

Industry Context

This announcement comes as Sanuwave is pursuing a merger with a special purpose acquisition company (SPAC), a common strategy for private companies seeking to go public. The issuance of convertible notes and warrants is a typical financing method for companies in this situation.

Comparison to Industry Standards

• The use of convertible notes and warrants is a common practice for companies seeking funding, especially in the biotech and medical device sectors.
• The 15% interest rate on the notes is relatively high, reflecting the risk associated with investing in a company that is not yet publicly traded and is undergoing a merger.
• The conversion price of $0.04 per share and the warrant exercise prices are relatively low, which could lead to significant dilution for existing shareholders if the company's stock price increases.
• The subordination of the note purchasers' rights to NH Expansion Credit Fund Holdings LP is a common practice in debt financing, where senior lenders have priority over junior lenders.
• The requirement to file a registration statement within a specific timeframe is a standard provision in agreements involving the issuance of securities to private investors.

Stakeholder Impact

• Shareholders may experience dilution due to the conversion of notes and exercise of warrants.
• Employees may benefit from the company's potential access to public markets.
• Customers and suppliers may see changes in the company's operations and financial stability.
• Creditors may be impacted by the subordination of the note purchasers' rights.

Next Steps

• The company needs to file a registration statement with the SEC within 60 days.
• The company needs to have the registration statement declared effective within 180 days.
• The company needs to complete the planned business combination with SEP Acquisition Corp.
• The company needs to obtain stockholder approval for the merger.
• The company needs to maintain the listing of its securities on Nasdaq following the merger.

Key Dates

Keywords

convertible notes, warrants, private placement, securities purchase agreement, merger, SEP Acquisition Corp, registration rights, common stock, dilution, reverse stock split